SERI Using TripleTOF 5600 to Validate Protein Biomarker for Dry Eye Syndrome

The institute purchased the device in December and expects that its speed will make it a good validation platform for a 400-patient trial to be done in collaboration with ocular pharmaceutical company Allergan.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.